Clinical Trials Browser

Renal Pelvis and Ureter Urothelial Carcinoma

Carcinoma, Transitional Cell

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Carcinoma, Transitional Cell

Urinary Bladder Neoplasms

Urinary Bladder Neoplasms

Non-Muscle Invasive Bladder Neoplasms

Urinary Bladder Neoplasms

Urinary Bladder Neoplasms

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Urinary Bladder Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Metastatic Urothelial Cancer

Non-Muscle Invasive Bladder Neoplasms

Urinary Bladder Neoplasms

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

Carcinoma, Transitional Cell

Urinary Bladder Neoplasms

Carcinoma, Transitional Cell

Muscle Invasive Bladder Cancer (MIBC)

Bone Neoplasms, Melanoma, Osteosarcoma, Urologic Neoplasms

Non-Muscle Invasive Bladder Neoplasms

Urinary Bladder Neoplasms

Urinary Bladder Neoplasms

Carcinoma, Transitional Cell

Urothelial Cancer of Renal Pelvis

Non-Muscle Invasive Bladder Neoplasms

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

Muscle Invasive Bladder Cancer

Muscle Invasive Bladder Urothelial Carcinoma

Carcinoma, Transitional Cell

Urinary Bladder Neoplasms

Urinary Bladder Neoplasms

Carcinoma, Transitional Cell

Urinary Bladder Neoplasms

Carcinoma, Transitional Cell

Non-Muscle Invasive Bladder Neoplasms

Adenocarcinoma of Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Clinical Trials

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

ADAPT-BLADDER

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

MoonRISe-1

IMGeS

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

GAIN-BCG

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

TROPHY U-01

MoonRISe-3

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

ABLE-22

A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma

Intravesical Gem/Doce in Patients With NMIBC

Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC

HARBOR

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

NeoSTOP-IT

NAUTICAL

Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma

Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma

HGNMIBC

COBRA

Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer

Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

GAIN INST

Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors